BIOGY:OTC-Biogaia AB ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.81

Change

0.00 (0.00)%

Market Cap

USD 0.80B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori–the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-10 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD 56.53B
MKKGY Merck KGaA ADR

N/A

USD 53.54B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 48.35B
HLNCF Haleon plc

N/A

USD 47.19B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 20.51B
SDZXF Sandoz Group AG

N/A

USD 17.55B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 17.29B
SDZNY Sandoz Group AG

N/A

USD 16.54B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 10.30B
IPSEY Ipsen SA ADR

N/A

USD 9.72B

ETFs Containing BIOGY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.10% 62% D 59% D-
Dividend Return 7.02% 100% F 93% A
Total Return 15.12% 69% C- 68% D+
Trailing 12 Months  
Capital Gain -6.00% 69% C- 50% F
Dividend Return 6.11% 86% B+ 74% C
Total Return 0.11% 71% C- 53% F
Trailing 5 Years  
Capital Gain 34.79% 87% B+ 66% D+
Dividend Return 22.72% 88% B+ 53% F
Total Return 57.51% 89% A- 66% D+
Average Annual (5 Year Horizon)  
Capital Gain -0.25% 40% F 33% F
Dividend Return 2.81% 40% F 38% F
Total Return 3.06% 86% B+ 63% D
Risk Return Profile  
Volatility (Standard Deviation) 20.98% 67% D+ 48% F
Risk Adjusted Return 13.38% 53% F 32% F
Market Capitalization 0.80B 91% A- 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.